DNAL1
Dynein axonemal light chain 1
Also known as: 1700010H15RiK, C14orf168, CILD16, DNAL1_HUMAN, MGC12435
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q4LDG9
- Gene
- DNAL1
- Ensembl
- ENSG00000119661
- Chromosome
- 14
- Canonical length
- 190 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Centriolar satellite,Centrosome,Basal body,Cytosol,Acrosome,Mid piece,Principal piece,End piece
OverviewNCBI Gene
This gene encodes an axonemal dynein light chain which functions as a component of the outer dynein arms complex. This complex acts as the molecular motor that provides the force to move cilia in an ATP-dependent manner. The encoded protein is expressed in tissues with motile cilia or flagella and may be involved in the movement of sperm flagella. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Jan 2011]
Canonical amino-acid sequenceUniProt
190 residues, UniProt reviewed canonical sequence.
>Q4LDG9|DNAL1
1 MAKATTIKEA LARWEEKTGQ RPSEAKEIKL YAQIPPIEKM DASLSMLANC EKLSLSTNCI
61 EKIANLNGLK NLRILSLGRN NIKNLNGLEA VGDTLEELWI SYNFIEKLKG IHIMKKLKIL
121 YMSNNLVKDW AEFVKLAELP CLEDLVFVGN PLEEKHSAEN NWIEEATKRV PKLKKLDGTP
181 VIKGDEEEDNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DNAL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 51 nTPM
Expression across tissuesHPA
Tissue
- testis: 51 nTPM
- fallopian tube: 22 nTPM
- retina: 17 nTPM
- thyroid gland: 15 nTPM
- choroid plexus: 15 nTPM
- parathyroid gland: 14 nTPM
Single-cell type
- late primary spermatocytes: 522 nCPM
- early spermatids: 307 nCPM
- respiratory ciliated cells: 232 nCPM
- fallopian tube ciliated cells: 189 nCPM
- endometrial ciliated cells: 161 nCPM
- epididymal efferent duct ciliated cells: 138 nCPM
Immune cell
- plasmacytoid DC: 5.3 nTPM
- basophil: 3.7 nTPM
- MAIT T-cell: 3.5 nTPM
- naive B-cell: 2.9 nTPM
- memory B-cell: 2.5 nTPM
- gdT-cell: 2.4 nTPM
Brain region
- choroid plexus: 59 nTPM
- hippocampal formation: 46 nTPM
- midbrain: 44 nTPM
- hypothalamus: 43 nTPM
- cerebellum: 43 nTPM
- basal ganglia: 42 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about DNAL1.
Disease | AllUniProt
Conditions DNAL1 is implicated in, by any mechanism.
- Ciliary dyskinesia, primary, 16 (CILD16) MIM:614017
Disease | GeneticClinVar
11 pathogenic / likely-pathogenic of 152 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Primary ciliary dyskinesia 16
- Primary ciliary dyskinesia
- Kartagener syndrome
Disease | AutoantibodyPubMed
Conditions in which antibodies against DNAL1 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for DNAL1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
15 publications
- Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2.
1988 · Hepatology · RCR 4.8 · 169 citations - A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens.
2004 · Hepatology · RCR 2.5 · 118 citations - Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease.
2004 · J Autoimmune Dis · RCR 2.5 · 102 citations - HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis.
2006 · J Hepatol · RCR 1.6 · 69 citations - Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview.
2002 · Eur J Intern Med · RCR 1.6 · 64 citations
Show 10 more
- Structural characterization of the second major cross-reactive idiotype group of human rheumatoid factors. Association with the VH4 gene family.
1990 · Arthritis Rheum · RCR 1 · 45 citations - Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity.
1994 · J Rheumatol · RCR 1 · 32 citations - Diagnostic autoantibodies for autoimmune liver diseases.
2017 · Clin Transl Immunology · RCR 0.8 · 21 citations - Autoantibody Profiling in a Cohort of Pediatric and Adult Patients With Autoimmune Hepatitis.
2016 · J Clin Lab Anal · RCR 0.7 · 17 citations - Autoantibody detection in type 2 autoimmune hepatitis using a chimera recombinant protein.
2002 · J Immunol Methods · RCR 0.6 · 23 citations - Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection.
2004 · J Autoimmun · RCR 0.5 · 18 citations - Characterization of the B cell response of patients with anti-liver cytosol autoantibodies in type 2 autoimmune hepatitis.
2003 · Eur J Immunol · RCR 0.5 · 20 citations - [Autoimmune hepatitis: Immunological diagnosis].
2017 · Presse Med · RCR 0.4 · 8 citations - Asymptomatic autoimmune hepatitis associated with anti-LC-1 autoantibodies.
1996 · J Pediatr Gastroenterol Nutr · RCR 0.1 · 2 citations - [Characteristics of clinical and laboratory indexes in patients with liver disease with positive anti-liver cytosol antibody].
2021 · Zhonghua Gan Zang Bing Za Zhi · RCR 0 · 1 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.95
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 1.19
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DNAL1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DNAL1 as an antibody target. Whether an autoantibody or antibody against DNAL1 could matter depends on whether native DNAL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DNAL1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label DNAL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...